Click Therapeutics

Click Therapeutics is committed to providing patients with digital prescription therapeutic solutions by developing and commercializing software. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ can bring about internal changes in individuals and are designed to be used either independently or in combination with other biotherapies. The company’s Clickometrics® adaptive data science platform continuously personalizes user experience to optimize patient engagement and treatment outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program has been rolled out nationwide in the United States to serve the public. Click is also active in several high-burden therapeutic areas, including major depressive disorder, schizophrenia, acute coronary syndrome, migraine, chronic pain, insomnia, COPD, obesity, and more. Its representative product, Clickotine, digitally delivers smoking cessation strategies such as teaching controlled breathing exercises, enabling users to log their smoking habits and feelings, sending motivational messages, and more. The application has been adopted by over 30 enterprises, including insurance companies.